Authors
Zhihui Chen, Mingchen Zhong, Jing Wu, Xiangru Ye, Zhonghua Li, Jing Wang, Yueru Tian, Shirong Li, Lei Zhou, Jie Ni, Jialin Jin, Wenhong Zhang
Published in
Nature communications. Volume 17. Issue 1. Sep 26, 2026. Epub Sep 26, 2026.
Abstract
Carbapenem-resistant Gram-negative infections are a global threat, yet their long-term pathogen-specific mortality dynamics and pandemic-era deviations remain unclear. In this secondary modelling analysis, we evaluate associated mortality under a no-infection counterfactual and attributable mortality under a drug-susceptible infection counterfactual for carbapenem-resistant Gram-negative infections overall and across seven constituent pathogen groups in 204 countries and territories from 1990 to 2021. Using age-period-cohort decomposition and Bayesian counterfactual modelling, we estimate 1.03 million associated (95% uncertainty interval, 0.90-1.17 million) and 0.22 million attributable (0.17-0.27 million) deaths from these infections in 2021. From 1990 to 2019, overall associated and attributable mortality rates increased by 0.82% (95% confidence interval, 0.77-0.87) and 0.90% (0.85-0.95) per year, respectively. South Asia has the fastest-rising associated and attributable mortality, whereas high-income regions decline. Among constituent pathogens, Klebsiella pneumoniae shows the fastest increase in mortality rates, while Pseudomonas aeruginosa shows declining associated but slightly rising attributable mortality. During 2020-2021, overall associated mortality falls 4.71% below pre-pandemic counterfactual projections, whereas attributable mortality does not change significantly. Here, we show divergent mortality trajectories by region, pathogen, and metric, motivating targeted, dual-metric surveillance and intervention strategies.
PMID:
42934241
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0